Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB:TRUFF) engaged Kala Bio's Researgency.ai to support clinical development of Filament Health's patented botanical psilocybin candidate PEX010.
The company announced a definitive arrangement to acquire Filament's business, including 76 issued patents across 15 families, noted PEX010 has Health Canada and FDA trial authorizations, positive Phase 2 data in alcohol use disorder, and supply to >70 clinical sites.
Red Light Holland (OTCQB: TRUFF) will acquire Filament Health via a statutory plan of arrangement, combining Filament's GMP manufacturing, Health Canada Dealer's Licence, FDA‑authorized clinical programs and 76 issued patents with Red Light's mass cultivation, brand presence and microdosing data.
The all‑share deal issues up to 182,447,452 consideration shares, leaves existing Red Light holders with ~70% post‑closing, and targets closing in Q2 2026 subject to approvals.
Red Light Holland (OTCQB: TRUFF) will acquire Filament Health by plan of arrangement to combine GMP pharmaceutical manufacturing, a Health Canada Level 8 Dealer's Licence, an FDA-authorized clinical program and 76 issued patents covering natural psilocybin technologies.
The all-share transaction issues up to 182,447,452 Consideration Shares, leaves existing Red Light shareholders with ~70% ownership post-close, and targets completion in Q2 2026.
Red Light Holland (OTCQB: TRUFF) reported Q3 2026 results for the three and nine months ended December 31, 2025, with total cash of $9.238M and revenue of $1.265M for the quarter (up 8.3% year-over-year). Gross profit fell to $0.358M (down 13.7% YoY) while G&A expenses declined 15.8%. The company ceased shiitake production at AEM and is pursuing strategic R&D, M&A evaluations, and distribution growth, including Netherlands truffle sales to over 125 retailers and expanded U.S. retail activity with Albertsons/Safeway.
Red Light Holland (OTCQB:TRUFF) reported Q2 2026 results and a corporate update for the quarter ended September 30, 2025. Key metrics: Revenue $0.754M (down 44.9% YoY), Gross profit $0.327M (down 68.7% YoY), Adjusted EBITDA loss $0.785M (worse 61.9% YoY), Cash $10.226M, Total assets $19.018M.
Operational highlights include expanded U.S. retail distribution with Albertsons/Safeway, new R&D milestones with DEA-registered Irvine Labs (5kg shipment; potency testing compatible with manufacturing), ASU collaboration, and appointment of Dr. Robin Carhart-Harris as scientific advisor. Company pursuing M&A, streamlining, and a Bitcoin allocation up to $2M.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs in California received a second, larger 5 kg shipment of naturally occurring psilocybin imported under a United States Controlled Substances import permit on November 19, 2025.
The shipment was processed under Irvine Labs' 2025 DEA quota after potency testing and process validation confirmed compatibility with medical‑grade manufacturing. The companies said this scale‑up will support expanded R&D toward standardized psilocybin products and clinical/therapeutic programs. The company also issued 3,250,719 common shares at a deemed price of $0.035 per share to arm's length creditors.
Red Light Holland (OTCQB: TRUFF) announced that its wholly owned subsidiary Happy Caps expands distribution with Albertsons Companies' Safeway banner to 123 stores across Oregon and Washington, up from 66 stores, with rollout the week of November 17, 2025 and a replenishment order the week of December 5, 2025 for the holiday season.
Key metrics: 4,428 units to be supplied (up from 2,376), locally produced in Oregon with Trailbridge Mushroom Farm, featuring Shiitake, Lion's Mane, and Oyster home grow kits. The release also discloses equity actions: 100,000 stock options at $0.05, 4,250,000 RSUs, and issuance of 5,611,250 shares to settle debt at $0.035 per share, including related-party RSU and share participation.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs received a second United States Controlled Substances import permit on October 14, 2025, authorizing the import equivalent to 5 kg of psilocybin truffles from Red Light Holland's Netherlands facility.
The company said this follows a Certificate of Analysis confirming psilocybin potency and process validation in September 2025 and will support expanded R&D into dehydration, packaging, shelf‑life extension, and standardized microdosing capsule development for potential medical‑grade manufacturing, government pilot programs, and clinical trials.
Red Light Holland (OTCQB:TRUFF), a producer of functional mushrooms and psilocybin truffles, has achieved a significant milestone by receiving an official Certificate of Analysis (COA) through Irvine Labs, its FDA-compliant and DEA-registered partner in California.
The COA confirms psilocybin potency and process validation for potential medical grade manufacturing applications, following successful testing of naturally derived psilocybin truffles from the company's Netherlands facility. The partnership is advancing proprietary dehydration and packaging processes for extended shelf life while maintaining product integrity.
The company is preparing for a larger planned psilocybin export under Irvine Labs' 2025 DEA quota allocation, targeting emerging therapeutic markets, government-funded pilot programs, and clinical trials.
Red Light Holland (OTCQB:TRUFF) announced a significant expansion of its Happy Caps Mushroom Farm partnership with Safeway. The company's store presence will increase by 86% to 123 locations across Oregon and Washington State, up from the initial 66 stores.
The expanded partnership includes two seasonal programs scheduled for late fall and holiday season 2025, featuring Shiitake, Lion's Mane, and Oyster mushroom home grow kits. The products will highlight "Made in Oregon" and "Certified Organic" certifications, with production through Trailbridge Farms in Oregon to ensure freshness and improved margins.